Last reviewed · How we verify
Dexamethasone Early
Dexamethasone is a synthetic glucocorticoid that suppresses inflammation and immune responses by binding to glucocorticoid receptors.
Dexamethasone is a synthetic glucocorticoid that suppresses inflammation and immune responses by binding to glucocorticoid receptors. Used for Respiratory distress syndrome in preterm neonates, Chronic lung disease of prematurity (bronchopulmonary dysplasia prevention).
At a glance
| Generic name | Dexamethasone Early |
|---|---|
| Sponsor | NICHD Neonatal Research Network |
| Drug class | Glucocorticoid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory/Neonatology |
| Phase | Phase 3 |
Mechanism of action
Dexamethasone reduces inflammation by inhibiting phospholipase A2, decreasing prostaglandin and leukotriene production, and suppressing cytokine release. In neonates with respiratory distress or chronic lung disease, early administration aims to reduce airway inflammation and improve respiratory outcomes. The 'Early' designation indicates this is an early intervention strategy in the neonatal period.
Approved indications
- Respiratory distress syndrome in preterm neonates
- Chronic lung disease of prematurity (bronchopulmonary dysplasia prevention)
Common side effects
- Hyperglycemia
- Hypertension
- Immunosuppression/increased infection risk
- Gastrointestinal perforation
- Growth suppression
Key clinical trials
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment (PHASE1, PHASE2)
- Screening Study of Combined Sequential Chemotherapy and Radiation Therapy for Early-stage NK/T-cell Lymphoma (PHASE2)
- A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma (PHASE2)
- A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma (PHASE3)
- A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma (PHASE2)
- Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX) (PHASE3)
- ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dexamethasone Early CI brief — competitive landscape report
- Dexamethasone Early updates RSS · CI watch RSS
- NICHD Neonatal Research Network portfolio CI